VISTAGEN THERAPEUTICS, INC. (VTGN) Return on equity 2017–2026
VISTAGEN THERAPEUTICS, INC. (VTGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-196.2%FY2026 · since FY2017: -1665.4% → -196.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -196.2% | -123.1 pp |
| FY2025 | -73.0% | -47.4 pp |
| FY2024 | -25.7% | +464.8 pp |
| FY2023 | -490.5% | -416.7 pp |
| FY2022 | -73.8% | -54.3 pp |
| FY2021 | -19.5% | — |
| FY2018 | -207.4% | +1458.0 pp |
| FY2017 | -1665.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More VTGN financial trends
VTGN RevenueVTGN Net incomeVTGN Net marginVTGN Gross profitVTGN Gross marginVTGN Operating incomeVTGN Operating marginVTGN Operating cash flowVTGN Free cash flowVTGN Capital expendituresVTGN Stock buybacksVTGN Dividends paidVTGN Total assetsVTGN Total liabilitiesVTGN Shareholders’ equityVTGN overview →